Limits...
Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier survival curve of TCGA data comparing high legumain expression group with low legumain expression group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4660395&req=5

f5: Kaplan–Meier survival curve of TCGA data comparing high legumain expression group with low legumain expression group.

Mentions: Three articles compared the 5-year survival rates between patients with LGMNHigh expression (51.7%; 298 cases) and those with LGMNLow expression (79.9%; 154 cases)131924. Since the studies were not significantly heterogeneous (P > 0.10, I2 = 0.0%), we used the fixed-effect model for pooled analysis and found a significant difference between the two groups (RR = 0.66; 95% CI: 0.57–0.76; P < 0.05). We collected 61 cases of patients with rectal cancer from the TCGA database. We analyzed the follow-up data and tumor mRNA data (HiSeq RNASeqV2). Kaplan–Meier survival analysis revealed that the LGMNHigh group had significantly shorter survival compared to the LGMNLow group (P < 0.05; Fig. 5).


Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Kaplan–Meier survival curve of TCGA data comparing high legumain expression group with low legumain expression group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4660395&req=5

f5: Kaplan–Meier survival curve of TCGA data comparing high legumain expression group with low legumain expression group.
Mentions: Three articles compared the 5-year survival rates between patients with LGMNHigh expression (51.7%; 298 cases) and those with LGMNLow expression (79.9%; 154 cases)131924. Since the studies were not significantly heterogeneous (P > 0.10, I2 = 0.0%), we used the fixed-effect model for pooled analysis and found a significant difference between the two groups (RR = 0.66; 95% CI: 0.57–0.76; P < 0.05). We collected 61 cases of patients with rectal cancer from the TCGA database. We analyzed the follow-up data and tumor mRNA data (HiSeq RNASeqV2). Kaplan–Meier survival analysis revealed that the LGMNHigh group had significantly shorter survival compared to the LGMNLow group (P < 0.05; Fig. 5).

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus